Abstract 2163P
Background
In France, cancer is the leading cause of death among men and the second leading cause among women. Currently, supportive care provided to cancer patients in community pharmacies are heterogeneous across the country. In order to structure and standardize pharmaceuticalsupportfor all cancer patients in primary care, TotumLab foundation has created the OncoPharma certification.
Methods
The OncoPharma certification is based on a framework that covers the activities of dispensing treatments andsupportingcancer patients, caregivers and relatives, from the time of diagnosis, during and after cancer, by the entire pharmacy team. The framework presents certified characteristics, the way to implement them, as well as documentary ressources and requested internal controls to ensure compliance. The development of the certification framework is the result of a multidisciplinary collaborative effort, bringing together all healthcare professionals involved in cancer patients care. The OncoPharma certification is accessible to all community pharmacies in France.
Results
In the certification framework, patient care is structured around 14 operational characteristics that are proposed and adapted to each individual situation. Since June 2022, the OncoPharma certification framework has been accredited by the French accreditation committee (COFRAC). This document allowed for the publication of the first clinical guideline for the management of cancer patients in community pharmacies by the Francophone Association of Supportive Oncology Care (AFSOS). As of April 2023, two pharmacies have been certified under OncoPharma, and over 40 others are in the process of certification.
Conclusions
This innovative project is the result of collective and multidisciplinary work to improve the quality of life of patients living with cancer. It promotes communication and coordination among healthcare professionals, as well as training and upskilling of pharmacy teams. This project is part of the continuous improvement and value creation in healthcare. Thanks to the Oncopharma certification, the community pharmacist plays a central role in the care of people with cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
TotumLab.
Funding
TotumLab.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2194P - Prospective observational study of physical activity measurement using wearable device as an alternative to ECOG PS in patients with advanced lung cancer
Presenter: Kentaro Ito
Session: Poster session 07
Resources:
Abstract
2195P - Targeted gene editing with CRISPR for the treatment of pleural mesothelioma
Presenter: Rodrigo Dominic Cerqueda
Session: Poster session 07
2196P - PET-CT detects response to treatment with ipilimumab and nivolumab in malignant mesothelioma far better than CT
Presenter: Daniel C. Christoph
Session: Poster session 07
2197P - Prognostic value of 18F-FDG-PET for patients with malignant pleural mesothelioma treated with double immunotherapy
Presenter: Solfrid Thunold
Session: Poster session 07
2198P - Clinicopathologic characteristics and outcomes to immune checkpoint inhibitor therapy in patients with HER2-altered metastatic non-small cell lung cancer
Presenter: Maisam Makarem
Session: Poster session 07
2199P - Immunohistochemical identification of clinical subtypes and potential therapeutic vulnerabilities of lung carcinoids based on multi-omic analysis
Presenter: Jules Derks
Session: Poster session 07
2200P - Spatiotemporal distribution of mediastinal neoplasms: A multi-center, hospital-based, systematic analysis
Presenter: Yu Jiang
Session: Poster session 07
2201P - Malignant pleural mesothelioma (MPM)-specific DNA methylation patterns in patients using liquid biopsies
Presenter: Sabine Schmid
Session: Poster session 07
2202P - Large cell neuroendocrine carcinoma (LCNEC) subtyping based on NEUROD1, ASCL1, POU2F3 and YAP1 expression
Presenter: Frank Heijboer
Session: Poster session 07
2203P - Uncovering prognostic transcriptomic differences in epithelioid malignant pleural mesothelioma
Presenter: Mario Occhipinti
Session: Poster session 07